Entecavir options and obstacles of an effective treatment for chronic hepatitis B;Entecavir Möglichkeiten und Grenzen einer effektiven Therapie der chronischen Hepatitis B

Deutsche Medizinische Wochenschrift

Volumn 135, Issue 1-2, 2010, Pages 32-37

  Cornberg, M ^a   Manns, M P ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Entecavir; HBV DNA; Hepatitis B; Resistance; Therapy

Indexed keywords

ADEFOVIR; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; TENOFOVIR; ANTIVIRUS AGENT; DRUG DERIVATIVE; GUANINE; VIRUS ANTIGEN;

ANTIVIRAL ACTIVITY; CHRONIC HEPATITIS; DRUG EFFICACY; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; REVIEW; BLOOD; CHRONIC DISEASE; CLINICAL TRIAL; DRUG EFFECT; DRUG RESISTANCE; HEPATITIS B VIRUS; MORTALITY; PATHOLOGY;

ANTIGENS, VIRAL; ANTIVIRAL AGENTS; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE; GUANINE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LIVER CIRRHOSIS;

EID: 73449146665     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0029-1244814     Document Type: Review

References (19)

1. Baraclude Fachinformation, Bristol-Myers Squibb Pharma EEIG. Uxbridge, Vereinigtes Königreich Stand: August 2008
2. Chang T T., Gish R G., de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006 354 1001-1010
3. Chen C J., Yang H I., Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006 295 1 65-73
4. Colonno R J., Rose R E., Pokornowski K, et al. Four year assessment of ETV resistance in nucleoside-naive and lamivudine refractory patients. J Hepatol 2007 46 S294-S294
5. Cornberg M, Protzer U, Dollinger M M., et al. [Prophylaxis, Diagnosis and Therapy of Hepatitis-B-Virus-[HBV-]Infection: upgrade of the guideline, AWMF-Register 021/011]. Z Gastroenterol 2007 45 525-574
6. Gish R G., Lok A S., Chang T T., et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007 133 1437-1444
7. Han S HB, Chang T T., Chao Y C., et al. Five Years of Continuous Entecavir for Nucleoside-Naive Hbeag[+] Chronic Hepatitis B: Results from Study Etv-901. Hepatology 2008 48 705A-706A
8. Iloeje U H., Yang H I., Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006 130 678-686
9. Lai C L., Elion R, Sherman M, et al. Entecavir [Etv] Therapy in Chronic Hepatitis B Patients Previously Treated with Adefovir [Adv] with Incomplete Response On-Treatment Or Relapse Off-Treatment. Journal of Hepatology 2009 50 S334
10. Lai C L., Shouval D, Lok A S., et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006 354 1011-1020
11. Lampertico P, Vigano M, Facchetti F, et al. Entecavir Is An Effective Treatment for Nuc-Naive Chronic Hepatitis B Patients in Clinical Practice: 48-Week Data from A Large Multicenter Cohort Study. Journal of Hepatology 2009 50 S333-S333
12. Liaw Y F., Chang T T., Wu S S., et al. Long-Term Entecavir Therapy Results in Reversal of Fibrosis/Cirrhosis and Continued Histologic Improvement in Patients with Hbeag[+] and Chronic Hepatitis B: Results from Studies Etv-022,-027 And-901. Hepatology 2008 48 4 706A-706A
13. Locarnini S. Molecular virology and the development of resistant mutants: implications for therapy. Semin Liver Dis 2005 25 Suppl 1 9-19
14. Lutgehetmann M, Schollmeyer J, Volz T, et al. Rescue Therapy with Combination of Entecavir and Tenofovir in Patients with Chronic Hbv, Advanced Fibrosis and Multiple Previous Treatment Failures Is Safe and Highly Efficient. J Hepatol 2009 50 S335-S335
15. Perz J F., Armstrong G L., Farrington L A., et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006 45 529-538
16. Reijnders J, Deterding K, Petersen J, et al. Antiviral Effect of Entecavir: Results from 160 Chronic Hepatitis B Patients in An International Multicenter Cohort Study. J Hepatol 2009 50 S10
17. Tenney D J., Rose R E., Baldick C J., et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009 49 1503-1514
18. Liaw Y F., Raptopoulou-Gigi M, Cheinquer S K., et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with evidence of hepatic decompensation. Hepatology 2009 50 505A-505A
19. Lange C M., Bojunga J, Hofmann W P., et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009 50 406A-406A